- Home
- LUCD vs IPA Comparison
LUCD vs IPA Comparison
Compare LUCD & IPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- IPA
- Stock Information
- Founded
- LUCD 2018
- IPA 1983
- Country
- LUCD United States
- IPA United States
- Employees
- LUCD N/A
- IPA N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- IPA Biotechnology: Pharmaceutical Preparations
- Sector
- LUCD Health Care
- IPA Health Care
- Exchange
- LUCD Nasdaq
- IPA Nasdaq
- Market Cap
- LUCD 105.0M
- IPA 98.9M
- IPO Year
- LUCD 2021
- IPA 2017
- Fundamental
- Price
- LUCD $1.23
- IPA $2.07
- Analyst Decision
- LUCD Strong Buy
- IPA Strong Buy
- Analyst Count
- LUCD 5
- IPA 2
- Target Price
- LUCD $3.65
- IPA $4.00
- AVG Volume (30 Days)
- LUCD 1.1M
- IPA 1.9M
- Earning Date
- LUCD 08-13-2025
- IPA 09-24-2025
- Dividend Yield
- LUCD N/A
- IPA N/A
- EPS Growth
- LUCD N/A
- IPA N/A
- EPS
- LUCD N/A
- IPA N/A
- Revenue
- LUCD $4,360,000.00
- IPA $17,744,713.00
- Revenue This Year
- LUCD $22.80
- IPA $18.76
- Revenue Next Year
- LUCD $221.19
- IPA $32.14
- P/E Ratio
- LUCD N/A
- IPA N/A
- Revenue Growth
- LUCD 14.74
- IPA 0.01
- 52 Week Low
- LUCD $0.73
- IPA $0.27
- 52 Week High
- LUCD $1.80
- IPA $3.25
- Technical
- Relative Strength Index (RSI)
- LUCD 56.02
- IPA 43.06
- Support Level
- LUCD $1.17
- IPA $1.82
- Resistance Level
- LUCD $1.54
- IPA $3.25
- Average True Range (ATR)
- LUCD 0.10
- IPA 0.32
- MACD
- LUCD 0.01
- IPA -0.12
- Stochastic Oscillator
- LUCD 45.54
- IPA 2.10
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.